Expression of Cathepsin L in Nasopharyngeal Carcinoma and Its Clinical Significance
Affiliations
Aim: To study the expression of cathepsin L in nasopharyngeal carcinoma (NPC), and analyze its relationship with clinicopathologic factors.
Methods: The expression of cathepsin L was determined immunohistochemically in NPC, adjacent normal nasopharyngeal tissues and metastatic cervical lymph nodes. The correlation between its protein expression and clinicopathologic parameters as well as with long term follow-up data in NPC was analyzed.
Results: The protein of cathepsin L was overexpressed in 47% primary tumor tissues, and in 89% metastatic cervical lymph node samples. Overexpression of cathepsin L was found to correlate with lymph node metastasis ( P = 0.04) and distant metastasis ( P = 0.01), and marginally with clinical stage and T classification, but not with patient age, gender and histological classification of tumor. Patients with overexpression of cathepsin L in tumor tissue had worse 5-year survival than those without such expression pattern ( P = 0.033). Multivariate survival analysis showed that cathepsin L protein expression level had a marginal significant correlation with prognosis of NPC.
Conclusion: Cathepsin L is a potential biomarker for prognosis of NPC and contributes to NPC metastasis.
miR-106b-5p inhibits the invasion and metastasis of colorectal cancer by targeting CTSA.
Ni S, Weng W, Xu M, Wang Q, Tan C, Sun H Onco Targets Ther. 2018; 11:3835-3845.
PMID: 30013364 PMC: 6038879. DOI: 10.2147/OTT.S172887.
Sudhan D, Pampo C, Rice L, Siemann D Int J Cancer. 2016; 138(11):2665-77.
PMID: 26757413 PMC: 4805507. DOI: 10.1002/ijc.29992.
Endostatin's emerging roles in angiogenesis, lymphangiogenesis, disease, and clinical applications.
Walia A, Yang J, Huang Y, Rosenblatt M, Chang J, Azar D Biochim Biophys Acta. 2015; 1850(12):2422-38.
PMID: 26367079 PMC: 4624607. DOI: 10.1016/j.bbagen.2015.09.007.
Cathepsin L targeting in cancer treatment.
Sudhan D, Siemann D Pharmacol Ther. 2015; 155:105-16.
PMID: 26299995 PMC: 4624022. DOI: 10.1016/j.pharmthera.2015.08.007.
Plasma cathepsin L: a prognostic marker for pancreatic cancer.
Singh N, Das P, Gupta S, Sachdev V, Srivasatava S, Gupta S World J Gastroenterol. 2014; 20(46):17532-40.
PMID: 25516668 PMC: 4265615. DOI: 10.3748/wjg.v20.i46.17532.